Harrow Health Inc (HROW) stock soared 5.21% on Wednesday during the pre-market session, outpacing the broader market rally. The surge came after promising Phase 3 trial results from Melt Pharmaceuticals, a company that was previously spun off from Harrow in 2019.
Melt Pharmaceuticals announced positive topline efficacy data from its pivotal Phase 3 study evaluating MELT-300, a non-IV, non-opioid sedative tablet combining midazolam and ketamine. The trial demonstrated that MELT-300 was statistically superior to both sublingual midazolam and placebo in providing successful procedural sedation for patients undergoing cataract surgery. Notably, MELT-300 exhibited a favorable safety profile generally comparable to placebo.
While Melt Pharmaceuticals is now an independent company, its positive trial results appear to have fueled investor optimism around Harrow Health. If MELT-300 gains FDA approval based on these data, it could offer an attractive non-opioid alternative for the over 5 million cataract surgeries performed annually in the U.S. This potential market opportunity has traders speculating on potential financial benefits for Harrow stemming from its previous ownership of Melt Pharmaceuticals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.